ArticleBMC cancer2022

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.

Shuguang Ju et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.